

a¹ conceded
4 body,] once per day in the evening or at night combined with at least one
5 pharmaceutically acceptable [carriers] carrier, to produce a reduction in
6 total and LDL cholesterol, triglycerides and Lp(a), with a significant increase
7 in HDL cholesterol.

a²
1 5. (Amended) A method as set forth in Claim 1 wherein said nicotinic acid or
2 compound metabolized to nicotinic acid by the body is prepared by
3 formulating the active compound with from about [5%] 5 to about [50%] 50
4 parts by weight of hydroxypropyl methylcellulose per 100 parts by weight
5 of tablet.

a³
1 7. (Amended) A method, as set forth in Claim 4, wherein said binder is [a
2 polymer having the repeating polymerization unit 1-ethenyl-2-pyrrolidone]
3 polyvinyl pyrrolidone.

Cancel claims 10-12 without prejudice or disclaimer.

Please add new claim 13 as follows:

a⁴
1 - -13. A method of treating hyperlipidemia in a hyperlipidemic comprising dosing
2 the hyperlipidemic with an effective antihyperlipidemic amount of a
3 compound metabolized to nicotinic acid by the body and selected from the
4 group consisting of nicotiny alcohol tartrate, d-glucitol hexanicotinate,
5 aluminum nicotinate, and, 1-alpha-tocopheryl nicotinate, once per day in the
6 evening or at night combined with at least one pharmaceutically acceptable
7 carrier, to produce a reduction in total and LDL cholesterol, triglycerides
8 and Lp(a), with a significant increase in HDL cholesterol. - -

REMARKS

Claims 1-12 are pending in this application. Claims 1-9 and 11 stand rejected under 35 U.S.C. § 112 in that, as the Examiner states, the specification does not adequately describe "compound metabolized nicotinic acid".